Potential impact of introducing a nonavalent HPV vaccination

Giorgio Bogani, Francesca Taverna, Claudia Lombardo, Mauro Signorelli, Valentina Chiappa, Jvan Casarin, Cono Scaffa, Umberto Leone Roberti Maggiore, Dario Recalcati, Antonino Ditto, Fabio Martinelli, Chiara Borghi, Stefania Perotto, Simone Ferrero, Domenica Lorusso, Francesco Raspagliesi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To test the theoretical utility of incorporating nonavalent vaccination against HPV into a clinical setting.

METHODS: The present retrospective study included data from consecutive patients who underwent HPV-DNA testing between January 1, 1998, and December 31, 2015. Changes in the prevalence of different HPV types were assessed during three periods (T1, 1998-2003; T2, 2004-2009; and T3, 2010-2015) using XY analysis.

RESULTS: The study included a total of 13 665 patients. Overall, 1361, 5130, and 7174 patients were included in the T1, T2, and T3 periods, respectively. The quadrivalent vaccine would have potentially protected against HPV in 71.5% (973/1361), 46.5% (2385/5130), and 26.5% (1901/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The nonavalent vaccine could have protected against HPV in 92.5% (1259/1361), 72.3% (3709/5130), and 58.1% (4168/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The proportion of patients with genital dysplasia grade 2+ who did not have infections with HPV genotypes covered by the quadrivalent or nonavalent vaccines increased across the three periods (P<0.001 for trend). For all study periods, the protection provided by the nonavalent vaccine would have been superior to the quadrivalent vaccine (χ2 test P<0.001).

CONCLUSION: The introduction of a nonavalent vaccine could improve protection against HPV infections and HPV-related genital dysplasia.

Original languageEnglish
Pages (from-to)338-342
Number of pages5
JournalInternational Journal of Gynecology and Obstetrics
Volume142
Issue number3
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Vaccination
Vaccines
Infection
Retrospective Studies
Genotype
DNA

Keywords

  • Adult
  • Female
  • Genotype
  • Humans
  • Middle Aged
  • Papillomavirus Infections/prevention & control
  • Papillomavirus Vaccines/administration & dosage
  • Prevalence
  • Retrospective Studies
  • Uterine Cervical Neoplasms/prevention & control
  • Vaccination/methods
  • Young Adult

Cite this

Potential impact of introducing a nonavalent HPV vaccination. / Bogani, Giorgio; Taverna, Francesca; Lombardo, Claudia; Signorelli, Mauro; Chiappa, Valentina; Casarin, Jvan; Scaffa, Cono; Leone Roberti Maggiore, Umberto; Recalcati, Dario; Ditto, Antonino; Martinelli, Fabio; Borghi, Chiara; Perotto, Stefania; Ferrero, Simone; Lorusso, Domenica; Raspagliesi, Francesco.

In: International Journal of Gynecology and Obstetrics, Vol. 142, No. 3, 09.2018, p. 338-342.

Research output: Contribution to journalArticle

Bogani, Giorgio ; Taverna, Francesca ; Lombardo, Claudia ; Signorelli, Mauro ; Chiappa, Valentina ; Casarin, Jvan ; Scaffa, Cono ; Leone Roberti Maggiore, Umberto ; Recalcati, Dario ; Ditto, Antonino ; Martinelli, Fabio ; Borghi, Chiara ; Perotto, Stefania ; Ferrero, Simone ; Lorusso, Domenica ; Raspagliesi, Francesco. / Potential impact of introducing a nonavalent HPV vaccination. In: International Journal of Gynecology and Obstetrics. 2018 ; Vol. 142, No. 3. pp. 338-342.
@article{cf12fb6459204e5097167164e85a6557,
title = "Potential impact of introducing a nonavalent HPV vaccination",
abstract = "OBJECTIVE: To test the theoretical utility of incorporating nonavalent vaccination against HPV into a clinical setting.METHODS: The present retrospective study included data from consecutive patients who underwent HPV-DNA testing between January 1, 1998, and December 31, 2015. Changes in the prevalence of different HPV types were assessed during three periods (T1, 1998-2003; T2, 2004-2009; and T3, 2010-2015) using XY analysis.RESULTS: The study included a total of 13 665 patients. Overall, 1361, 5130, and 7174 patients were included in the T1, T2, and T3 periods, respectively. The quadrivalent vaccine would have potentially protected against HPV in 71.5{\%} (973/1361), 46.5{\%} (2385/5130), and 26.5{\%} (1901/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The nonavalent vaccine could have protected against HPV in 92.5{\%} (1259/1361), 72.3{\%} (3709/5130), and 58.1{\%} (4168/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The proportion of patients with genital dysplasia grade 2+ who did not have infections with HPV genotypes covered by the quadrivalent or nonavalent vaccines increased across the three periods (P<0.001 for trend). For all study periods, the protection provided by the nonavalent vaccine would have been superior to the quadrivalent vaccine (χ2 test P<0.001).CONCLUSION: The introduction of a nonavalent vaccine could improve protection against HPV infections and HPV-related genital dysplasia.",
keywords = "Adult, Female, Genotype, Humans, Middle Aged, Papillomavirus Infections/prevention & control, Papillomavirus Vaccines/administration & dosage, Prevalence, Retrospective Studies, Uterine Cervical Neoplasms/prevention & control, Vaccination/methods, Young Adult",
author = "Giorgio Bogani and Francesca Taverna and Claudia Lombardo and Mauro Signorelli and Valentina Chiappa and Jvan Casarin and Cono Scaffa and {Leone Roberti Maggiore}, Umberto and Dario Recalcati and Antonino Ditto and Fabio Martinelli and Chiara Borghi and Stefania Perotto and Simone Ferrero and Domenica Lorusso and Francesco Raspagliesi",
note = "{\circledC} 2018 International Federation of Gynecology and Obstetrics.",
year = "2018",
month = "9",
doi = "10.1002/ijgo.12546",
language = "English",
volume = "142",
pages = "338--342",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Potential impact of introducing a nonavalent HPV vaccination

AU - Bogani, Giorgio

AU - Taverna, Francesca

AU - Lombardo, Claudia

AU - Signorelli, Mauro

AU - Chiappa, Valentina

AU - Casarin, Jvan

AU - Scaffa, Cono

AU - Leone Roberti Maggiore, Umberto

AU - Recalcati, Dario

AU - Ditto, Antonino

AU - Martinelli, Fabio

AU - Borghi, Chiara

AU - Perotto, Stefania

AU - Ferrero, Simone

AU - Lorusso, Domenica

AU - Raspagliesi, Francesco

N1 - © 2018 International Federation of Gynecology and Obstetrics.

PY - 2018/9

Y1 - 2018/9

N2 - OBJECTIVE: To test the theoretical utility of incorporating nonavalent vaccination against HPV into a clinical setting.METHODS: The present retrospective study included data from consecutive patients who underwent HPV-DNA testing between January 1, 1998, and December 31, 2015. Changes in the prevalence of different HPV types were assessed during three periods (T1, 1998-2003; T2, 2004-2009; and T3, 2010-2015) using XY analysis.RESULTS: The study included a total of 13 665 patients. Overall, 1361, 5130, and 7174 patients were included in the T1, T2, and T3 periods, respectively. The quadrivalent vaccine would have potentially protected against HPV in 71.5% (973/1361), 46.5% (2385/5130), and 26.5% (1901/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The nonavalent vaccine could have protected against HPV in 92.5% (1259/1361), 72.3% (3709/5130), and 58.1% (4168/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The proportion of patients with genital dysplasia grade 2+ who did not have infections with HPV genotypes covered by the quadrivalent or nonavalent vaccines increased across the three periods (P<0.001 for trend). For all study periods, the protection provided by the nonavalent vaccine would have been superior to the quadrivalent vaccine (χ2 test P<0.001).CONCLUSION: The introduction of a nonavalent vaccine could improve protection against HPV infections and HPV-related genital dysplasia.

AB - OBJECTIVE: To test the theoretical utility of incorporating nonavalent vaccination against HPV into a clinical setting.METHODS: The present retrospective study included data from consecutive patients who underwent HPV-DNA testing between January 1, 1998, and December 31, 2015. Changes in the prevalence of different HPV types were assessed during three periods (T1, 1998-2003; T2, 2004-2009; and T3, 2010-2015) using XY analysis.RESULTS: The study included a total of 13 665 patients. Overall, 1361, 5130, and 7174 patients were included in the T1, T2, and T3 periods, respectively. The quadrivalent vaccine would have potentially protected against HPV in 71.5% (973/1361), 46.5% (2385/5130), and 26.5% (1901/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The nonavalent vaccine could have protected against HPV in 92.5% (1259/1361), 72.3% (3709/5130), and 58.1% (4168/7174) of patients in T1, T2, and T3, respectively (P<0.001 for trend). The proportion of patients with genital dysplasia grade 2+ who did not have infections with HPV genotypes covered by the quadrivalent or nonavalent vaccines increased across the three periods (P<0.001 for trend). For all study periods, the protection provided by the nonavalent vaccine would have been superior to the quadrivalent vaccine (χ2 test P<0.001).CONCLUSION: The introduction of a nonavalent vaccine could improve protection against HPV infections and HPV-related genital dysplasia.

KW - Adult

KW - Female

KW - Genotype

KW - Humans

KW - Middle Aged

KW - Papillomavirus Infections/prevention & control

KW - Papillomavirus Vaccines/administration & dosage

KW - Prevalence

KW - Retrospective Studies

KW - Uterine Cervical Neoplasms/prevention & control

KW - Vaccination/methods

KW - Young Adult

U2 - 10.1002/ijgo.12546

DO - 10.1002/ijgo.12546

M3 - Article

C2 - 29858884

VL - 142

SP - 338

EP - 342

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 3

ER -